Latest Oncotype DX Stories
Approval to Begin Clinical Laboratory Operations in Support of PraediCare-Dx(TM) Portfolio CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- EUTROPICS Inc., a privately held company
Complete Data to be Submitted for Presentation at the 2014 San Antonio Breast Cancer Symposium REDWOOD CITY, Calif., June 11, 2014 /PRNewswire/ -- Genomic Health, Inc.
The study was led by researchers at the National Cancer Institute (NCI)─designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and Montefiore Einstein Center for Cancer Care and was published online today in the Journal of the National Cancer Institute (JNCI).
BRONX, N.Y., June 3, 2014 /PRNewswire-USNewswire/ -- A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread,
Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/
New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc.
New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy
REDWOOD CITY, Calif., May 23, 2014 /PRNewswire/ -- Genomic Health, Inc.
New Analysis Suggests Oncotype DX Predicts Recurrence Risk After Prostatectomy Regardless of Post-Surgery Treatment REDWOOD CITY, Calif., May 20, 2014 /PRNewswire/ -- Genomic Health,
Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD
- The word or words serving to define another word or expression, as in a dictionary entry.